13-12-2018
MULTI-12 K
PEDIATRIC , 03/10/2018 AH
לע רשואו קדבנ הז ןולע
ךיראתב תואירבה דרשמ ידי
ילוי
2003
Physicians’ Prescribing Information
MULTI-12/K
1
PEDIATRIC
Multiple Vitamins for Infusion
Multi-12/K
1
Pediatric
is a multiple vitamin supplement containing the following vitamins:
Vial 1
Ascorbic acid
80 mg
Vitamin A
2300 IU
Vitamin D
400 IU
Thiamine (as hydrochloride)
1.2 mg
Riboflavin (as phosphate)
1.4 mg
Pyridoxine hydrochloride
1 mg
Niacinamide
17 mg
d
-Panthenol
5 mg
Vitamin E (
dl
-alpha tocopheryl acetate)
7 IU
Vitamin K
0.2 mg
Also contains: polysorbate 80, 1.25%, sodium hydroxide and/or
hydrochloric acid to adjust pH and water for injection.
Vial 2
Biotin
20 mcg
Folic Acid
140 mcg
Vitamin B
(cyanocobalamin)
1 mcg
Also contains: mannitol 7.5 %, sodium citrate and/or citric acid to
adjust pH and water for injection.
INDICATIONS
Multi-12/K
1
Pediatric
is indicated for use as a multiple vitamin supplement for infants and children up
to 11 years of age.
Its administration helps to maintain plasma vitamin levels and helps to prevent depletion of endogenous
stores of the vitamins and development of subsequent deficiency symptoms.
It is also indicated in other situations where there are increased requirements for vitamins due to stress
situations such as surgery, extensive burns, fractures and other trauma, severe infectious diseases, and
comatose states.
The physician should not await the development of clinical signs of vitamin deficiency before initiating
vitamin therapy. The use of a multivitamin product obviates the need to speculate on the status of
individual vitamin nutriture.
Multi-12/K
1
Pediatric
through
intake
these
necessary
vitamins,
contributes
towards
maintenance of the body's normal resistance and repair processes.
MULTI-12 K
PEDIATRIC , 03/10/2018 AH
CONTRAINDICATIONS
Known hypersensitivity to any of the vitamins in this product or a pre-existing hypervitaminosis.
MULTI-12 K
PEDIATRIC , 03/10/2018 AH
PRECAUTIONS
General: Unlike the adult formulation, Multi-12, and the original pediatric formulation, Multi-12
Pediatric, this product contains Vitamin K
1
.
Caution should be used when administering
Multi-12/K
1
Pediatric
to neonates undergoing concomitant
parenteral therapy with drugs containing polysorbate 80. If deemed necessary, to limit the concomitant
administration of polysorbate 80, discontinue
Multi-12/K
1
Pediatric
therapy for a few days and resume
it when the other drug therapy has been ceased.
Drug
Interactions
Multi-12/K
1
Pediatric
physically
compatible
with
acetazolamide,
aminophylline, ampicillin, or moderately alkaline solutions. It has been reported that folic acid is
unstable in the presence of calcium salts such as calcium gluconate.
Carcinogenicity
: Carcinogenicity studies have not been performed.
ADVERSE REACTIONS
There have been rare reports of anaphylactoid reactions following large intravenous doses of thiamine.
The risk, however, is negligible if thiamine is co-administered with other B vitamins. There have been no
reports of fatal anaphylactoid reactions associated with pediatric multivitamin preparations.
There have been rare reports of the following types of reactions:
Dermatologic: rash, erythema, pruritus.
CNS: headache, dizziness, agitation, anxiety.
Ophthalmic: diplopia.
Allergic: urticaria, periorbital and digital edema.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product.
Any suspected adverse events should be reported to the Ministry of Health according to the
National Regulation by using an online form
http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.
gov.il
SYMPTOMS AND TREATMENT OF OVERDOSAGE
The fat-soluble vitamins A, D and E can accumulate to harmful levels. Water-soluble vitamins, however,
are readily excreted in the urine. Treatment of vitamin overdosage usually consists of withdrawal of the
vitamin.
DOSAGE AND ADMINISTRATION
Multi-12/K
1
Pediatric
should not be given as a direct, undiluted intravenous injection as it may give
rise to dizziness, faintness and possible tissue irritation.
Multi-12/K
1
Pediatric must be diluted prior to
intravenous infusion.
For administration to infants and children weighing
3 kg up to 11 years of age:
Add one daily
dose [the entire contents of Vial 1 (4 mL) and of Vial 2 (1 mL)] to not less than 100 mL of 5% Dextrose
Injection or 0.9% Sodium Chloride Injection.
MULTI-12 K
PEDIATRIC , 03/10/2018 AH
For administration to infants weighing
1500 g and < 3 kg:
The daily dose is 65% of the contents of
Vial 1 and Vial 2, added to not less than 100 mL of 5% Dextrose Injection or 0.9% Sodium Chloride
Injection.
For administration to infants weighing < 1500 g:
The daily dose is 30% of the contents of Vial 1 and
Vial 2, added to not less than 100 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.
MULTI-12 K
PEDIATRIC , 03/10/2018 AH
After
Multi-12/K
1
Pediatric
is diluted in an intravenous infusion, the resulting solution should be
refrigerated unless it is to be administered immediately, and in any event should be administered within
24 hours. Discard any unused portions.
Some of the vitamins in this product, particularly vitamins A, D, and riboflavin, are light-sensitive.
Exposure to light should be minimized.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to
administration, whenever solution and container permit.
AVAILABILITY OF DOSAGE FORMS
Multi-12/K
1
Pediatric
is available as five single use two vial set: 5 x Vial 1 containing 4 mL and 5 x
Vial 2 containing 1 mL.
Store between 2 and 8 °C.
Protect from light.
Discard unused portion.
Latex-Free Stoppers: Stoppers contain no dry natural rubber.
Drug Registration No.:
139.34.30692.00
MANUFACTURER
SANDOZ CANADA INC.,
Quebec, Canada .
IMPORTER
Teva Medical Marketing Ltd.,
Haorgim St.
8
, Ashdod 77100.